What is the role of maintenance chemotherapy in the treatment of Waldenstrom macroglobulinemia (WM)?

Updated: Aug 06, 2020
  • Author: Joseph M Tuscano, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print


The role of maintenance therapy in patients with WM/LPL remains controversial, as there are no prospective trials demonstrating a benefit. However, some centers extrapolate from the data on indolent lymphoma and consider rituximab maintenance in patients who respond to a rituximab-containing induction regimen. [19]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!